Drug intelligence / Profile preview

propofol + lidocaine + magnesium sulfate

Development stage: Unknown
Lead developer: AkzoNobel
Modality: Small Molecules
Administration: Intravenous

Overview

A combination of three drugs used to reduce pain associated with propofol injection during anesthesia induction. Propofol is an intravenous anesthetic agent, while lidocaine (a local anesthetic) and magnesium sulfate are administered as pretreatment to mitigate the pain commonly experienced during propofol injection, especially when administered into small veins on the dorsum of the hand.

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on propofol + lidocaine + magnesium sulfate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on propofol + lidocaine + magnesium sulfate.

Explore the full profile